首页> 外文OA文献 >Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

【2h】

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

机译：评估抗CD40抗体异霉素在原发性Sjögren综合征患者中：多期，随机，双盲，安慰剂控制，概念证明研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Benjamin A Fisher; Antonia Szanto; Wan-Fai Ng; Michele Bombardieri; Maximilian G Posch; Athena S Papas; Arwa M Farag; Thomas Daikeler; Bettina Bannert; Diego Kyburz; Alan J Kivitz; Steven E Carsons; David A Isenberg; Francesca Barone; Simon J Bowman; Pascal Espié; David Floch; Cyrielle Dupuy; Xiaohui Ren; Petra M Faerber; Andrew M Wright; Hans-Ulrich Hockey; Michael Rotte; Julie Milojevic; Alexandre Avrameas; Marie-Anne Valentin; James S Rush; Peter Gergely;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The efficacy of cevimeline hydrochloride in the treatment of xerostomia in Sj?gren’s syndrome in southern Chinese patients: a randomised double-blind, placebo-controlled crossover study [J] . K. C. M. Leung, A. S. McMillan, M. C. M. Wong, Clinical Rheumatology . 2008,第4期

机译：盐酸西维美林在治疗南方华氏综合征干燥口干症中的功效：一项随机，双盲，安慰剂对照的交叉研究
2. Patient and investigator reported outcomes suggest improvements upon treatment with the novel anti-CD40 monoclonal antibody CFZ533 in patients with primary Sjogren's syndrome: a phase iia double-blind, placebo-controlled randomized trial [J] . Papas Athena S., Farag Arwa M., Fisher Benjamin, Clinical and experimental rheumatology . 2018,第3Suppla112期

机译：患者和调查员报告结果表明，在原发性Sjogren综合征患者中，用新型抗CD40单克隆抗体CFZ533治疗改善：IIA双盲，安慰剂对照随机试验
3. Patient and investigator reported outcomes suggest improvements upon treatment with the novel anti-CD40 monoclonal antibody CFZ533 in patients with primary Sjogren's syndrome: a phase iia double-blind, placebo-controlled randomized trial [J] . Papas Athena S., Farag Arwa M., Fisher Benjamin, Clinical and experimental rheumatology . 2018,第3Suppla112期

机译：患者和调查员报告结果表明，在原发性Sjogren综合征患者中，用新型抗CD40单克隆抗体CFZ533治疗改善：IIA双盲，安慰剂对照随机试验
4. Predicting lymphoma outcomes and risk factors in patients with primary Sjögren’s Syndrome using gradient boosting tree ensembles [C] . Vasileios C. Pezoulas, Themis P. Exarchos, Athanasios G. Tzioufas, Annual International Conference of the IEEE Engineering in Medicine and Biology Society . 2019

机译：使用梯度增强树组合预测原发性干燥综合征患者的淋巴瘤结局和危险因素
5. Immunopathogenic Mechanisms in Primary Sj?gren’s Syndrome [D] . Bj?rk, Albin. 2021

机译：原发性SJ的免疫致病机制？GREN的综合征
6. Concise report: Effect of rituximab on a salivary gland ultrasound score in primary Sjögren’s syndrome: results of the TRACTISS randomised double-blind multicentre substudy [O] . Benjamin A Fisher, Colin C Everett, John Rout, -1

机译：简明报告：利妥昔单抗对原发性干燥综合征患者唾液腺超声评分的影响：TRACTISS随机双盲多中心亚研究的结果
7. FRI0174 SUBCUTANEOUS DOSING OF THE NOVEL ANTI-CD40 ANTIBODY ISCALIMAB ACHIEVES TARGET DRUG EXPOSURE AND CLINICAL EFFICACY IN PRIMARY SJÖGREN’S SYNDROME; RESULTS OF A PHASE IIA RANDOMISED OPEN LABEL TWO ARM PARALLEL GROUP TRIAL [O] . Benjamin Fisher, Antónia Szántó, Wan Fai Ng, 2019

机译：Fri0174新型抗CD40抗体的皮下给药Iscalimab达到原发性Sjögren综合征的靶药暴露和临床疗效; IIA的结果随机开放标签两臂并联组试验

Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study

著录项

引文网络

相似文献

相关主题

期刊订阅